Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

EpiPen Alternative Could Hit Pharmacy Shelves Next Year

XTALKS VITALS NEWS

EpiPen

A two-pack of EpiPens now sells for $608, which is a 548 percent price increase over the product’s cost ten years ago.

Share this!

October 27, 2016 | by Sarah Hand, M.Sc.

While Mylan’s controversial EpiPen currently holds significant market share, the medical device is about to face some stiff competition. Kaleo Pharma – the company that owns the rights to a rival medical device – will reportedly begin marketing their product in early 2017.

The device, called Auvi-Q, was previously sold by Sanofi, however it was pulled from the market in 2015 amid concerns that the auto-injector was delivering inaccurate doses of epinephrine. Kaleo has yet to announce details regarding the pricing of the medical device.

“We’re focusing on returning Auvi-Q to the market as an alternative product that all patients can afford,” Kaleo chief executive Spencer Williamson told StatNews. “… We understand that price is central to this conversation. … I can assure you that at the end of the day, after we work with all the stakeholders, patients will have a low out-of-pocket cost.”

Kaleo’s decision to reintroduce the medical device comes at an opportune time as pricing for the EpiPen has become a controversial topic. Mylan is just one of the companies in the pharmaceutical and medical device industries who has faced criticism for their pricing practices.



A two-pack of EpiPens now sells for $608, which is a 548 percent price increase over the product’s cost ten years ago. In response to the rising costs, which are being passed from insurers onto patients, Mylan could begin selling a generic version of the EpiPen for $300.

Currently, the only available alternative to the EpiPen is a medical device known as the Adrenaclick, marketed by Amedra Pharmaceuticals. The device has seen an increased number of prescriptions lately, as physicians seek to help patients find a lower-cost version of the lifesaving medication.

While Teva Pharmaceuticals and Adamis have been developing EpiPen alternatives of their own, the US Food and Drug Administration (FDA) has not yet approved these devices. The regulatory agency has faced criticism over their approval processes, particularly when it comes to products, like the EpiPen, who have a near-monopoly on the market.

Like Mylan, Kaleo has recently been involved in some drug pricing inquiries of their own. In early 2016, Kaleo was contacted by two US Senators regarding the company’s decision to raise the price of an old drug, used to reverse opioid overdoses.

According to Kaleo, in an effort to get the Auvi-Q back on the market, they have “conducted a thorough manufacturing assessment and invested in new technology and quality systems to ensure accurate, reliable and consistent delivery from the product.” At present, it’s unclear exactly what regulatory steps Kaleo has taken to get this EpiPen alternative back into the pharmacy.


Keywords: Medical Device, Pharmaceutical Pricing, Prescriptions


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News


Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News


Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.